The "Diaper Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
Hello, ladies and gentlemen, and thank you for standing by for GreenTree's fourth-quarter and full-year 2020 earnings conference call. GreenTree's earnings release was distributed earlier today and is available on our IR website at ir.998.com, as well as on PR Newswire services. On the call from GreenTree are Mr. Alex Xu, chairman and chief executive officer; Ms. Selina Yang, chief financial officer; and Mr.
10 of the best places to see outdoor art in the UK: chosen by readers. Many a lockdown walk has been brightened by a piece of modern art. Readers pick their favourites, from seafronts and forests to more urban settings
Delivers very strong financial results in unprecedented yearRevenues more than doubled in FY 2020 compared to FY 2019 to a record €128.4 million, with Q4 2020 revenues nearly quadrupling year-over-year to a record €70.3 millionAchieved highest annual adjusted EBITDA in CENTOGENE’s history, driven by COVID-19 testing revenues in H2 of 2020, even with continuous investment in the Company’s rare disease core business100,000 patients added to rare disease-centric database and biobank in 2020, an increase of 20%Diagnostics recovery and newly signed Pharma partnership deals indicate a return to solid core business growth in 2021 Virtual Investor Event outlining future strategy and direction of the Company to be held on June 22nd CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 15, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today provided an update on its corporate progress and announced financial results for the fourth quarter of 2020 and full year ended December 31, 2020. Executive Commentary “During a challenging 2020 for our industry and society at large, we demonstrated an ability to be nimble as well as leverage our expertise to help address COVID-19,” said Andrin Oswald, M.D., Chief Executive Officer at CENTOGENE. “It is a direct result of our team’s commitment to patients, deep knowledge of medical diagnostics, and innovative science-backed initiatives. Accordingly, we are pleased to see the significant revenue achieved with our commercial COVID-19 testing, and are positioned to invest the associated financial contributions into our core rare disease business. As such, we expect to see continued expansion in our key assets, such as our database and biobank, artificial intelligence, and research and development of rare genetic diseases. We anticipate a return to solid core business growth in 2021.” Richard Stoffelen, CENTOGENE’s Chief Financial Officer, added, “We are pleased with CENTOGENE’s performance in 2020, particularly in achieving record revenue growth and the highest annual adjusted EBITDA in the Company’s history amid a global pandemic. As we continue into 2021, we will use our significantly strengthened balance sheet and extensive knowledge of rare diseases to continue to deliver value to our patients and shareholders.” Financial Highlights Revenues more than doubled in 2020 compared to 2019 for a record €128.4 millionQ4 2020 revenues nearly quadrupled year-over-year to a record €70.3 millionCommercial COVID-19 testing contributed €59.8 million in revenues in Q4 2020, up from €27.4 million in Q3 2020Achieved highest annual adjusted EBITDA in Company’s historyPharma revenues decreased 21%, while Clinical Diagnostics revenues (excl. COVID) decreased 19% compared to FY 2019 Business Highlights Throughout 2020 and into 2021, CENTOGENE has continued solidifying its leading position in the rare disease space: Pharma Pharma Collaborations Steady momentum of new pharma partnerships, with 16 new deals signed in 2020, including nine on clinical trial support and five on sponsored genetic testingContinued expansion of database- and biobank-related pharma collaborations further strengthens the Company’s ability to advance the areas of genetic diagnostics, clinical trial support and patient classification, and target and drug discovery Clinical Studies CENTOGENE currently has 16 ongoing observational clinical studies and longitudinal observational clinical studies to validate/monitor biomarkers, covering several disease categories, such as Parkinson’s disease, transthyretin amyloidosis, and inborn errors of metabolismThe Company recently reached a key milestone of 10,000 participants in its global Parkinson’s disease study (Rostock International Parkinson's Disease (ROPAD) Study). In 2018, CENTOGENE entered into a strategic collaboration with Denali Therapeutics for the targeted global identification and recruitment of Parkinson’s disease patients with mutations in the LRRK2 gene Diagnostics Order Intake The sample order intakes number for the core Diagnostics segment decreased by 19% compared to 2019. The most significant impact was in H1 2020, and sample order intake demonstrated an upward trend in H2 2020, with Q4 2020 being nearly on par with Q4 2019 Scientific Publications CENTOGENE’s scientific study underlining the power of Genome Sequencing (GS) as a first-line, stand-alone diagnostic test was selected as the European Journal of Human Genetics Editor’s Choice 2021 and Reader’s Choice 2020In 2020, the Company authored 55 peer-reviewed scientific publications focused on several diseases, including Gaucher and Fabry, as well as the advancements of diagnostic technologies, such as Whole Genome Sequencing COVID-19 COVID-19 Testing Offering Leveraged Company’s diagnostic expertise and resources to offer COVID-19 testing, including the opening of eight COVID-19 test centers and processing over one million samples for SARS-CoV-2 testing in 2020 Financial Guidance Diagnostics recovery and newly signed Pharma partnership deals indicate a return to solid core business growth for 2021. Regarding the Company’s COVID-19 segment, uncertainties remain around global vaccine rollout, epidemiological impact of new mutations and testing policies, making accurate predictions impossible. Based on the current trajectory as of Q1 2021, CENTOGENE anticipates revenues from the COVID-19 segment to be at least on par with 2020. Virtual Investor Event CENTOGENE plans to host an investor event on June 22, 2021, to provide an update on its strategy and progress in the rare disease space. The investor event will be held virtually and hosted on the Company’s website. Webcast and Conference Call Details Management will host a conference call today, April 15, 2021, at 8 a.m. EDT to discuss financial results and recent corporate developments. You may register for the conference call at http://emea.directeventreg.com/registration/6009679. Upon registering, each participant will be provided with participant dial in numbers, a direct event passcode, and a unique registrant ID. The webcast of the conference call and the related earnings presentation will also be available on the Investor Relations page of the Company’s website at http://investors.centogene.com. Further Information Further information on the Company’s Full Year 2020 Earnings, including the management’s discussion and analysis of financial condition and results of operations, can be found by visiting EDGAR on the SEC website at www.sec.gov, as well as the Investor Relations page of the Company’s website at http://investors.centogene.com. About CENTOGENE CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with over 3.9 billion weighted data points from approximately 600,000 patients representing over 120 different countries as of December 31, 2020. The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of December 31, 2020, the Company collaborated with over 30 pharmaceutical partners. Important Notice and Disclaimer This press release contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities, and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward- looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties, and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2020, on Form 20-F filed with the SEC on April 15, 2021, and other current reports and documents furnished to or filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. CONTACT: Media Contact: CENTOGENE Lennart Streibel Investor Relations email@example.com FTI Consulting Bridie Lawlor O’Boyle +1.917.929.5684 firstname.lastname@example.org
Beazer Homes (NYSE: BZH) (www.beazer.com) has scheduled the release of its financial results for the quarter ended March 31, 2021 on Thursday, April 29, 2021 after the close of the market. Management will host a conference call on the same day at 5:00 PM ET to discuss the results.
Kimco Realty Corp. (NYSE: KIM), one of North America’s largest publicly traded owners and operators of open-air, grocery-anchored shopping centers and mixed-use assets, and Weingarten Realty Investors (NYSE: WRI), a grocery-anchored Sun Belt shopping center owner, manager and developer, today announced that they have entered into a definitive merger agreement under which Weingarten will merge with and into Kimco, with Kimco continuing as the surviving public company. The transaction brings together two industry-leading retail real estate platforms with highly complementary portfolios, creating the preeminent open-air shopping center and mixed-use real estate owner in the country. The increased scale in targeted growth markets, coupled with a broader pipeline of redevelopment opportunities, positions the company to create significant value for its shareholders. The combined company is expected to have a pro forma equity market capitalization of approximately $12.0 billion and a pro forma total enterprise value of approximately $20.5 billion.
Iron Mountain Incorporated (NYSE: IRM), the storage and information management services company, today announced that it has signed two leases with an existing U.S. based Fortune 100 technology customer, at its AZP-2 data center in Phoenix, Arizona. The first lease represents a one megawatt expansion, which is expected to commence in the third quarter of 2021. The second lease was for a five megawatt deployment, which is expected to commence in the fourth quarter of 2021. Iron Mountain’s data center solutions met all of the customer’s requirements, including scalable capacity, network proximity to other deployments, and a design that provided flexibility and reliability.
Every investor wants to make as much money as possible in the stock market, and it can be tempting to take on riskier investments in hopes of getting rich overnight. The unfortunate truth, though, is that there's no way to "get rich quick" in the stock market -- at least without facing the risk of losing more than you gain. While these three types of investments may seem promising on the surface, they can cost you more than you think.
NICE Actimize, a NICE (Nasdaq: NICE) business, has been ranked by global advisory and consulting firm Quadrant Knowledge Solutions as a Technology Leader in its recently released "SPARK Matrix™ Anti-Money Laundering (AML) Solution, 2021 report. The Quadrant Knowledge Solutions study, which provides competitive analysis and a ranking of the leading anti-money laundering vendors in the form of its proprietary SPARK Matrix, scored NICE Actimize and its consolidated Anti-Money Laundering solutions highest across technology excellence. To download a copy of the complimentary report, please click here.
Alarm.com to Announce 2021 First Quarter Financial Results on May 4, 2021.
Talenom Plc Inside information 15 April 2021 at 13:30 EESTTalenom strengthens its business in the financial management of associations by acquiring Balance-Team Oy and raises its net sales guidance Talenom Plc has acquired the Helsinki-based Balance-Team Oy, which specialises in financial management for associations. Talenom already has a business unit focused on associations and foundations, which, with the acquisition of Balance-Team Oy will make Talenom a leading provider of financial management services for nonprofit organisations in Finland. The share capital of Balance-Team Oy will be transferred to Talenom on 15 April 2021. The acquired company was formed on 1 April 2021 in a demerger in which non-accounting activities and assets were separated from the company. Net sales of the transferred accounting business for the financial year ended 31 December 2020 were 2.7 million euros (31 December 2019: 2.8 million euros) and EBITDA was 1.0 million euros (31 December 2019: 1.0 million euros). As a result of the acquisition, Talenom revises its financial outlook and raises its guidance for 2021 regarding net sales. New guidance for 2021Net sales for 2021 are expected to amount to 80–84 million euros and operating profit is expected to be 14–16 million euros. Previous guidance for 2021 According to the previous guidance published on 18 March 2021, net sales for 2021 were expected to amount to 78–82 million euros and operating profit was expected to be 14–16 million euros. Due to integration costs and the depreciation of the transaction price, the acquisition will not materially increase operating profit for the financial year in the short term, especially as the business will be transferred to Talenom after the most profitable spring months. Completion of the acquisition The transaction will be carried out by acquiring the entire share capital of the company and paid in the form of new Talenom Plc shares subscribed for in a directed share issue and with cash. The transaction price is 5.3 million euros, of which 2.65 million euros will be paid in cash and 2.65 million euros in shares. The potential additional purchase price, if the operational and financial targets are reached, is 0.7 million euros at maximum. “The entrepreneurs of Balance-Team Oy, Susanna and Jyrki Aaltonen, together with their staff, are leading experts in the financial management of associations in Finland. For this reason, I am particularly honoured to have them on board to develop our existing business, which provides financial management services that meet the specific needs of associations," says Otto-Pekka Huhtala, CEO of Talenom. “From the start of our operations, it has been important for us to provide our customers with high-quality, personalised service that takes into account the special features of the associations. With the digitalization of the accounting industry, and as customer expectations increase and regulatory requirements become stricter, we have looked for additional resources to help develop our operations. Talenom's values, strategy and vision of the future of the industry are in line with our thoughts. We believe that together, we can provide our customers with the most advanced solutions in the industry and offer secure employment and new career paths for our employees,” say Susanna and Jyrki Aaltonen, who will continue their work at Talenom’s employ. Financial information on Balance-Team Oy 1,000 eurosBalance-Team Oy*Results1-12/20201-12/2019Net sales2,7022,768EBITDA1,044990 Opening balance sheet of the transferring company, estimate15 April 2021Goodwill and other intangible assets397Other assets460Total assets 857 Equity374Non-current liabilities-Current liabilities483Total shareholders’ equity and liabilities857 Number of employees20 *) The company was formed on 1 April 2021 in a demerger in which non-accounting activities were separated from the company. The figures reflect the share of the transferring accounting firm business. The 235,003 new Talenom shares subscribed for in the directed share issue related to the transaction will be registered in the Trade Register approximately on 19 April 2021. The total number of Talenom Plc shares is 43,700,625 shares following the registration of the new shares. The number of new shares issued corresponds to approximately 0.54% of all Talenom Plc shares outstanding before the new shares are issued. The new shares will carry shareholders rights as of their registration day. The shares issued in the share issue will later be admitted to trading on the stock exchange list of Nasdaq Helsinki Oy. TALENOM PLCBOARD OF DIRECTORS Further information:Otto-Pekka HuhtalaCEO, Talenom Plctel. +358 40 703 email@example.com Talenom is an agile and progressive accounting firm established in 1972. Our business idea is to make day-to-day life easier for entrepreneurs with the easiest-to-use digital tools on the market and highly automated services. In addition to comprehensive accounting services, we support our customers’ business with a wide range of expert services as well as financing and banking services. Our vision is to provide unbeatable accounting and banking services for SMEs. Talenom has a history of strong growth – the average annual increase in net sales was approximately 15.5% between 2005 and 2020. At the end of 2020, Talenom had 912 employees in Finland and Sweden at a total of 47 locations. Talenom’s share is quoted on the main list of the Helsinki Stock Exchange. DISTRIBUTION:Nasdaq HelsinkiMain mediawww.talenom.fi
Maximus announced today that its Board of Directors has approved a quarterly cash dividend of $0.28 per share.
AFM13 monotherapy: Reported positive data from the preplanned interim analysis for the registration-directed trial in PTCLAFM13 combination with NK cells: Announced 100% objective response rate in four response evaluable patients, including 2 complete responsesAFM24 monotherapy: AFM24 (phase 1/2a study) completed cohort 4 and is enrolling and treating patients in cohort 5; expansion cohorts expected to start in the second half of 2021 AFM24 combination with NK cells: IND application cleared by the FDA for the combination of AFM24 with NKGen Biotech’s SNK-01 NK autologous cell therapyAFM24 combination with anti PD-L1 antibody: Established a collaboration with Roche to clinically explore the combination of AFM24 with atezolizumab (Tecentriq®) Made continued progress in advancing and forming partnerships with Genentech and Roivant, which triggered payments to AffimedPro forma cash and cash equivalents as of December 31, 2020 were approximately €244.5 million (inclusive of Q1 equity offering and loan proceeds) with anticipated cash runway into the second half of 2023Conference call and webcast scheduled for April 15, 2021 at 8:30 a.m. EDT Heidelberg, Germany, April 15, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the year ended December 31, 2020 and provided an update on clinical and corporate progress. “2020 was an important year for Affimed. We continued to build on the strong foundation of our scientific discoveries and made significant progress across all our programs. We broadened our clinical pipeline, added new collaborations, built a strong balance sheet, appointed key senior management executives and ensured that our programs stayed on track through the global pandemic,” said Dr. Adi Hoess, CEO of Affimed. “We entered 2021 with strong momentum, and the recently announced positive outcome of our interim futility analysis for our registration directed study of AFM13 as monotherapy in PTCL patients, and initial data from the trial investigating AFM13 pre-complexed natural killer cells in Hodgkin lymphoma patients provide further validation for our three-pronged development strategy. As we look ahead into 2021, we anticipate numerous additional updates as we advance our programs.” Clinical Stage Program Updates Three-pronged Development Strategy Based on preclinical and clinical data, Affimed is pursuing development of its innate cell engagers (ICE®) as monotherapy, and in combination with adoptive NK cell transfer and PD-1/PD-L1 checkpoint inhibitors. AFM13 (CD30/CD16A) In March 2021, Affimed reported positive results from the preplanned interim futility analysis for AFM13-202, its phase 2 registration-directed study of AFM13 (CD16A/CD30) as monotherapy in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL). The futility analysis demonstrated that the response rate in Cohort A achieved the predefined threshold for continuation of the study. The response rate in Cohort B was sufficiently comparable to allow merging of both cohorts into a single cohort for all patients with CD30 >1%, per the study protocol. Evidence of anti-tumor response was observed in both cohorts with complete and partial responses. The trial will continue by combining the high- and low-CD30 expressing cohorts into one.In April 2021, Affimed reported positive initial clinical data from the investigator sponsored trial (IST) at The University of Texas MD Anderson Cancer Center evaluating increasing doses of cord-blood derived NK cells pre-complexed with AFM13 (CD16A/CD30) followed by three weekly infusions of AFM13 monotherapy in patients with recurrent or refractory CD30 positive lymphomas. As of March 31, 2021, all four response evaluable patients, including three patients in cohort 1 (1x106 AFM13-cbNK/kg) and one patient in cohort 2 (1x107 AFM13-cbNK/kg), have achieved an objective response, including two complete responses, according to investigator assessments by Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC). All four patients had relapsed / refractory Hodgkin lymphoma and were heavily pretreated, with between four and 14 previous lines of therapy which in all cases included brentuximab vedotin (Adcetris®) and anti-PD1 antibodies. AFM24 (EGFR/CD16A) AFM24-101, the phase 1/2a clinical trial of AFM24, the EGFR/CD16A targeted ICE® for patients with EGFR-expressing solid tumors, completed dose cohort 4 (160 mg) and patients are currently being enrolled and treated in dose cohort 5 (320 mg). Affimed expects to provide an update on the dose escalation and initiate the dose expansion cohorts during 2021.An investigational new drug (IND) application was cleared by the U.S. Food and Drug Administration to investigate the combination of AFM24 with NKGen Biotech’s (formerly known as NKMax America) autologous NK cell therapy, SNK01, in a first-in-human proof of concept (POC) trial in patients with EGFR-expressing tumors. Affimed expects to initiate the study in the second half of 2021. Affimed entered into a clinical collaboration with Roche for a phase 1/2a study evaluating AFM24 in combination with the PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) in EGFR-expressing solid tumors. The phase 1 portion of the study will establish a dosing regimen and assess safety for the combination; in the subsequent phase 2a portion of the study, the clinical activity of the combination will be evaluated in specific tumor types. Affimed expects to initiate the study in the second half of 2021.Preclinical data was presented at AACR 2021 showing the potential of AFM24 as monotherapy and in combination with NK cells. As monotherapy, AFM24 induces tumor cell killing independent of KRAS mutations; and, in combination with adoptive NK cells, it leads to AFM24 dose-dependent tumor regression. Preclinical and Partnered Programs AFM28 progressed further in IND-enabling studies and Affimed expects an IND application will be filed in the first half of 2022.In November 2020, Affimed entered into a licensing and strategic collaboration agreement with Roivant Sciences and granted Roivant a license to AFM32 with options for additional ICE® molecules against targets not included in Affimed’s current pipeline. AFM32 will be investigated in solid tumors. In August 2020, Affimed announced that Genentech’s RO7297089, a CD16A/BCMA targeting ICE®, is actively recruiting patients into a first-in-human phase 1 trial resulting in the achievement of a milestone payment under the terms of the collaboration.Affimed entered a collaboration with Artiva Biotherapeutics to assess feasibility and activity of pre-manufactured, co-vialed, cryopreserved, off-the-shelf NK cell combination therapeutics. The R&D collaboration is assessing the feasibility and preclinical activity of combinations of Artiva’s allogeneic NK cell product AB-101 and Affimed’s ICE® molecules, building on earlier preclinical studies demonstrating synergistic cytotoxic activity. Other Corporate Updates In January 2021, Affimed completed a $115 million underwritten public offering to accelerate and expand the development and manufacturing of its clinical and preclinical ICE® molecules.In January 2021, Affimed entered into a financing agreement with Silicon Valley Bank for up to €25 million in term loans, with €10 million available at closing. Full Year 2020 Financial Highlights As of December 31, 2020, cash, cash equivalents and current financial assets totaled €146.9 million compared to €104.1 million on December 31, 2019. The pro forma cash position as of December 31, 2020, including net proceeds from the January 2021 underwritten public offering and the first tranche of the Silicon Valley Bank loan, would be approximately €244.5 million. Based on its current operating plan and assumptions, Affimed anticipates that its cash and cash equivalents will support operations into the second half of 2023. Net cash used in operating activities for the year ended December 31, 2020 amounted to €19.4 million compared to €29.1 million for the year ended December 31, 2019. The amount received in 2020 includes an initial upfront payment and committed funding of €33.3 million (US$ 40 million) from the Roivant collaboration. Total revenue for the year ended December 31, 2020 was €28.4 million compared with €21.4 million for the year ended December 31, 2019. Revenue for 2020 and 2019 predominantly relate to the Genentech collaboration. Collaboration revenue for the year ended December 31, 2020 amounted to €27.8 million, with €26.2 million from the Genentech collaboration and €1.4 million from the Roivant collaboration. Collaboration revenue of €19.7 million for the year ended December 31, 2019 was from the Genentech collaboration. Research and development expenses for 2020 increased 14.2% from €43.8 million in the year ended December 31, 2019 to €50.0 million in the year ended December 31, 2020, due to higher expenses for AFM24 and our other projects and infrastructure investments. General and administrative expenses increased 33.6% from €10.3 million in the year ended December 31, 2019 to €13.7 million in the year ended December 31, 2020. In 2020, general and administrative expenses were largely comprised of personnel expenses of €6.3 million and legal, consulting and audit costs of €5.6 million. Finance costs for the year ended December 31, 2020 were €6.6 million, compared to finance income of €15 thousand for the year ended December 31, 2019. Finance costs for the year ended December 31, 2020 were largely comprised of foreign exchange losses related to assets denominated in U.S. dollars as a result of the weakening of the U.S. dollar compared to the Euro during the year. Net loss for the year ended December 31, 2020 was €41.4 million, or €0.50 per common share compared with a net loss of €32.4 million, or €0.50 per common share, for the year ended December 31, 2019. The weighted number of common shares outstanding for the year ended December 31, 2020 was 83.5 million. Additional information regarding these results is included in the notes to the consolidated financial statements as of December 31, 2020 and “Item 5. Operating and Financial Review and Prospects,” which will be included in Affimed’s Annual Report on Form 20-F as filed with the U.S. Securities and Exchange Commission (SEC). Note on International Financial Reporting Standards (IFRS) Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board. None of the financial statements were prepared in accordance with Generally Accepted Accounting Principles in the United States. Affimed maintains its books and records in Euro. Conference Call and Webcast Information Affimed will host a conference call and webcast today, April 15, 2021 at 8:30 a.m. EDT to discuss fourth quarter, year-end 2020 financial results and recent corporate developments. The conference call will be available via phone and webcast. To access the call, please dial +1 (646) 741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference passcode 4271307 approximately 15 minutes prior to the call. A live audio webcast of the conference call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts_cp/. A replay of the webcast will be accessible at the same link for 30 days following the call. About Affimed N.V. Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com. Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the potential of AFM13, AFM24, and our other product candidates, the value of our ROCK® platform, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our collaboration activities, our ability to develop commercial functions, clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us, impacts of the COVID-19 pandemic, the benefits to Affimed of orphan drug designation and the risks, uncertainties and other factors described under the heading “Risk Factors” in Affimed’s filings with the SEC. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. Investor Relations Contact Alexander FudukidisDirector, Head of Investor RelationsE-Mail: firstname.lastname@example.orgTel.: +1 (917) 436-8102 Affimed N.V. Consolidated statements of comprehensive income / (loss) (in € thousand) 2020 2019 2018 Revenue 28,360 21,391 23,735 Other income - net 626 290 1,515 Research and development expenses (49,989) (43,791) (35,148) General and administrative expenses (13,715) (10,266) (9,638) Operating loss (34,718) (32,376) (19,536) Finance income / (costs) - net (6,647) 15 60 Loss before tax (41,365) (32,361) (19,476) Income taxes (1) (4) (1) Loss for the period (41,366) (32,365) (19,477) Other comprehensive income / (loss) Items that will not be reclassified to profit or lossEquity investments at fair value OCI - net change in fair value (242) (632) (4,731) Other comprehensive income / (loss) (242) (632) (4,731) Total comprehensive Loss (41,608) (32,997) (24,208) Earnings / (loss) per share in € per share (undiluted = diluted) (0.50) (0.50) (0.32) Weighted number of common shares outstanding 83,471,559 64,242,396 60,514,407 Affimed N.V.Consolidated statements of financial position (in € thousand) ASSETS December 31, 2020 December 31, 2019 Non-current assets Intangible assets 1,718 137 Leasehold improvements and equipment 2,226 2,291 Long term financial assets 20,042 3,193 Right-of-use assets 940 824 24,926 6,445 Current assets Cash and cash equivalents 146,854 95,234 Financial assets 0 8,902 Trade and other receivables 2,439 1,482 Inventories 246 296 Other assets 1,260 0 150,799 105,914 TOTAL ASSETS 175,725 112,359 EQUITY AND LIABILITIES Equity Issued capital 983 762 Capital reserves 345,164 270,451 Fair value reserves 1,720 1,962 Accumulated deficit (275,874) (234,508) Total equity 71,993 38,667 Non-current liabilities Borrowings 231 278 Contract liabilities 35,992 37,961 Lease liabilities 482 272 Total non-current liabilities 36,705 38,511 Current liabilities Trade and other payables 11,394 10,674 Provisions 0 517 Borrowings 92 2,105 Lease liabilities 492 532 Contract liabilities 55,049 21,353 Total current liabilities 67,027 35,181 TOTAL EQUITY AND LIABILITIES 175,725 112,359 Affimed N.V.Consolidated statements of cash flows (in € thousand) Cash flow from operating activities 2020 2019 2018 Income / (loss) for the period (41,366) (32,365) (19,477) Adjustments for the period: - Income taxes 1 4 1 - Depreciation and amortisation 1,115 906 403 - Net gain / loss from disposal of leasehold improvements and equipment 34 (5) 25 - Share based payments 3,381 2,469 2,035 - Finance income / costs - net 6,647 (15) (60) (30,188) (29,006) (17,073) Change in trade and other receivables (1,065) 33 (322) Change in inventories 50 (36) (19) Change in other assets (1,260) 340 121 Change in trade, other payables, provisions and contract liabilities 12,848 (791) 66,856 Cash used in operating activities (19,615) (29,460) 49,563 Interest received 294 628 218 Paid interest (78) (224) (342) Paid income tax (1) 0 (1) Net cash used in operating activities (19,400) (29,056) 49,438 Cash flow from investing activities Purchase of intangible assets (9) (150) (30) Purchase of leasehold improvements and equipment (431) (1,324) (691) Cash received from the sale of leasehold improvements and equipment 0 0 1 Cash paid for investments in financial assets (8,101) (45,131) (14,029) Cash received from maturity of financial assets 16,547 50,945 0 Cash paid for investments in long term financial assets 0 0 (861) Net cash used for investing activities 8,006 4,340 (15,610) Cash flow from financing activities Proceeds from issue of common shares 74,195 31,373 25,113 Transaction costs related to issue of common shares (2,294) (2,215) (1,701) Proceeds from borrowings 0 562 0 Repayment of lease liabilities (521) (405) 0 Repayment of borrowings (2,128) (3,277) (2,917) Cash flow from financing activities 69,252 26,038 20,495 Exchange-rate related changes of cash and cash equivalents (6,238) (917) 669 Net changes to cash and cash equivalents 57,858 1,322 54,323 Cash and cash equivalents at the beginning of the period 95,234 94,829 39,837 Cash and cash equivalents at the end of the period 146,854 95,234 94,829 Affimed N.V.Consolidated statements of changes in equity (in € thousand) Issued capital Capital reserves Fair value reserves Accumulateddeficit Total equity Balance as of January 1, 2018 468 213,778 7,325 (182,667) 38,904 Issue of common shares 156 23,171 23,327 Exercise of share based payment awards 71 71 Equity-settled share based payment awards 2,035 2,035 Loss for the period (19,477) (19,477) Other comprehensive income (4,731) (4,731) Balance as of December 31, 2018 624 239,055 2,594 (202,144) 40,129 Balance as of January 1, 2019 624 239,055 2,594 (202,144) 40,129 Issue of common shares 138 28,901 29,039 Exercise of share based payment awards 26 26 Equity-settled share based payment awards 2,469 2,469 Loss for the period (32,365) (32,365) Other comprehensive income (632) (632) Balance as of December 31, 2019 762 270,451 1,962 (234,508) 38,667 Balance as of January 1, 2020 762 270,451 1,962 (234,508) 38,667 Issue of common shares 205 68,341 68,546 Exercise of share based payment awards 16 2,991 3,007 Equity-settled share based payment awards 3,381 3,381 Loss for the period (41,366) (41,366) Other comprehensive income (242) (242) Balance as of December 31, 2020 983 345,164 1,720 (275,874) 71,993
German Economy Minister Peter Altmaier said on Thursday he expected the government to significantly lift its full-year 2021 forecast for gross domestic product growth after leading institutes revised their own estimates. "We'll not only be able to stop the economic slump this year, we can reverse it and regain our old strength next year," Altmaier said, adding he would present the government's updated GDP growth forecast on April 27. In January, the government predicted GDP growth of 3% for 2021, following a drop of 4.9% in the previous year caused by the coronavirus pandemic.
Layering is bang on trend.
Global Eco-Friendly Bitumen Market to Reach $126,743. 58 by 2025. Market Report Coverage - Eco-Friendly Bitumen Market Segmentation. • By Source- Bio-Based, Recycled Bitumen, Natural Bitumen.New York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Eco-Friendly Bitumen Market - A Global Market and Regional Analysis: Focus on Applications, Products, Grades, Patent Analysis, and Country Analysis - Analysis and Forecast, 2020-2025" - https://www.reportlinker.com/p06061847/?utm_source=GNW • By Grade- Paving Grade Bitumen, Oxidized Bitumen, Hard Grade Bitumen, Others• By Application- Construction, Waterproofing, Paints and Coatings, OthersRegional Segmentation• North America – U.S., Canada, and Mexico• Europe – France, Germany, Spain, and Italy• U.K.• Asia-Pacific and Japan – Australia, South Korea, Japan, and India• China• Middle East and Africa – South Africa, Saudi Arabia• South America - BrazilGrowth Drivers• Increasing Demand for Sustainable Roads• Escalating global roadways and highways construction activities• Stringent government regulations for reducing carbon footprints• Increasing demand for reducing emissions from building and construction sectorMarket Challenges• Lack of awareness among consumers coupled with high cost of the productMarket Opportunities• Rising Inclination toward Alternative Binders in Road PavementsKey Eco-Friendly Bitumen Companies ProfiledAmerican Gilsonite Company, Agarwal Industrial Corporation Limited, Avello Bioenergy, Bharat Petroleum Corporation Ltd, Gilsonite CO., Jalnidhi Bitumen Specialties PVT. Ltd, and Royal Dutch Shell, among othersKey Questions Answered in this Report:• What are the current trends in the global bitumen industry regarding sustainability?• How has the global bitumen market been impacted by the introduction of eco-friendly bitumen? • What is the growth prospect of bio-based bitumen in road construction? • Can the future of the construction industry be bio-based? • Which are the major patents filled in the market? • What is the role of the government regarding environmental issues and safety that is changing the landscape of the eco-friendly bitumen industry? • Which bitumen source is expected to lead the eco-friendly bitumen market by 2025? • What was the market value of the leading segments and sub-segments of the market in 2019, and how is the market estimated to grow during the forecast period 2020-2025? • How is the industry expected to evolve during the forecast period 2020-2025? • What are the key developmental strategies that are implemented by the key players to sustain in the competitive market? • What are the key growth regions in the eco-friendly bitumen market? • What are the major challenges inhibiting the growth of the eco-friendly bitumen market?Market OverviewEco-friendly bitumen is an emerging market which is projected to follow an upward growth trend primarily driven by growing consumers inclination towards sustainable construction. Eco-friendly bitumen is available in multiple forms in market such as bio-based bitumen, recycled bitumen, and natural bitumen. Recycled bitumen registered the highest demand in global eco-friendly bitumen market owing to increasing awareness regarding road pavements recycling and environmental benefits associate with the same.Major growth driver for global eco-friendly bitumen market is escalating highways and roadways construction activities across the world. several economies have witnessed high growth in transportation infrastructure due to increasing vehicle sales, population, and urbanization. In India, highway construction increased by a CAGR of 21.4% from the year 2016-19 (as per IBEF, November 2020 report) with the construction of 10,855 km of highways. Construction being the major application of eco-friendly bitumen, growing highways contrition is projected to remain the primary factor for uplifting product demand till 2025.Despite of having a positive growth prospect, global eco-friendly bitumen demand faced a major setback in 2020 due to declining construction activities in most parts of the world. due to COVID 19 outbreak, various countries have witnessed a fall in construction activities in 2020 which has negatively impacted the demand of eco-friendly bitumen in the same year. for instance, Europe registered a decline of over 25% in construction activities in the April-May 2020 period. Such huge falls in construction industry has a severe impact on eco-friendly bitumen demand in 2020. however, with the industry regaining its original pace, the eco-friendly bitumen demand is also forecasted to follow a significant growth trend in the near future.Competitive LandscapeThe competitive landscape of the eco-friendly bitumen market comprises of strategies adopted by key players to strengthen their market presence.The global eco-friendly bitumen market has witnessed partnerships, collaboration, joint ventures, new product launches, and some business expansion strategies by various industry players.The market is still in its emerging phase in the market, and the investment in the market is less. however, the market has a high growth potential growth, and therefore, various construction companies are adopting measures to expand their product portfolios in green and sustainable bitumen alternatives. For instance, In July 2020, CEMEX launched an eco-friendly single asphalt solution for cycle lanes and footpaths, which eliminates the need for multi-layering surfaces. The product has achieved a carbon footprint reduction. Such measures are expected to increase awareness regarding sustainable construction materials in the industry while also positively influencing global eco-friendly bitumen market growth.As global construction industry is moving towards sustainable construction materials, companies are increasingly adopting strategies to strengthen their product portfolios in eco-friendly products by practicing mergers, acquisitions, joint ventures, and various such techniques.Companies in the eco-friendly bitumen market have expressed a huge interest in collaborations and partnerships to widen their customer bases and strengthen their product portfolios.For instance, in October 2019, Shell Bitumen entered into a partnership with Tiki Tar for selling bitumen to customers in the pavement industry, including state and national highways in India.Global eco-friendly bitumen market has a moderate competition due to presence of less established brands in the market. However, with increasing number of new entrants, the industry rivalry in global eco-friendly bitumen market is poised to increase in coming years. key players in the market are Royal Dutch Shell, American Gilsonite Company and Kraton Corporation, among others.Countries Covered• North America• U.S.• Canada• Mexico• South America• Brazil• Europe• Germany• France• Italy• Spain• U.K.• Middle East and Africa• South Africa• Saudi Arabia• China• Asia-Pacific and Japan• South Korea• Japan• Australia• IndiaRead the full report: https://www.reportlinker.com/p06061847/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Paris, Thursday, April 15th, 2021 At the Annual Shareholders’ Meeting of LVMH Moët Hennessy Louis Vuitton held on Thursday, April 15th, 2021, approval was given for the payment of a dividend for financial year 2020 of 6.00 Euros per share. Taking into account the 2.00 Euros paid on Thursday, December 3rd, 2020, the balance of 4.00 Euros will be paid on Thursday, April 22nd, 2021. The last trading day with dividend rights is Monday, April 19th, 2021. LVMH LVMH Moët Hennessy Louis Vuitton is represented in Wines and Spirits by a portfolio of brands that includes Moët & Chandon, Dom Pérignon, Veuve Clicquot Ponsardin, Krug, Ruinart, Mercier, Château d’Yquem, Domaine du Clos des Lambrays, Château Cheval Blanc, Colgin Cellars, Hennessy, Glenmorangie, Ardbeg, Belvedere, Woodinville, Volcán de Mi Tierra, Chandon, Cloudy Bay, Terrazas de los Andes, Cheval des Andes, Cape Mentelle, Newton, Bodega Numanthia, Ao Yun, Château d'Esclans and Château du Galoupet. Its Fashion and Leather Goods division includes Louis Vuitton, Christian Dior Couture, Celine, Loewe, Kenzo, Givenchy, Fendi, Emilio Pucci, Marc Jacobs, Berluti, Loro Piana, RIMOWA, Patou. LVMH is present in the Perfumes and Cosmetics sector with Parfums Christian Dior, Guerlain, Parfums Givenchy, Kenzo Parfums, Perfumes Loewe, Benefit Cosmetics, Make Up For Ever, Acqua di Parma, Fresh, Fenty Beauty by Rihanna and Maison Francis Kurkdjian. LVMH's Watches and Jewelry division comprises Bvlgari, Tiffany & Co, TAG Heuer, Chaumet, Dior Watches, Zenith, Fred and Hublot. LVMH is also active in selective retailing as well as in other activities through DFS, Sephora, Le Bon Marché, La Samaritaine, Groupe Les Echos, Cova, Le Jardin d’Acclimatation, Royal Van Lent, Belmond and Cheval Blanc hotels. LVMH CONTACTS Analysts and investors Chris Hollis LVMH + 33 1 44 13 21 22 Media Jean-Charles Tréhan LVMH + 33 1 44 13 26 20 MEDIA CONTACTS France Aymeric Granet Brune Diricq / Charlotte Mariné Publicis Consultants + 33 1 44 82 47 20 France Michel Calzaroni / Olivier Labesse / Hugues Schmitt / Thomas Roborel de Climens DGM Conseil + 33 1 40 70 11 89 Italy Michele Calcaterra, Matteo Steinbach SEC and Partners + 39 02 6249991UK Hugh Morrison, Charlotte McMullen Montfort Communications + 44 7921 881 800 USNik Deogun / Blake SonnensheinBrunswick Group+ 1 212 333 3810 China Daniel Jeffreys Deluxewords +44 772 212 6562 +86 21 80 36 04 48 Attachment 2020 DIVIDEND VA
Parliamentarian Will Amos apologised for the incident saying it was an honest mistake
Dublin, April 15, 2021 (GLOBE NEWSWIRE) -- The "Malaysia Tire Market, By Vehicle Type (Passenger Car, Two-Wheeler, Light Commercial Vehicles, Medium & Heavy Commercial Vehicles & OTR Vehicles), By Demand Category (OEM vs. Replacement), By Radial vs. Bias, By Company, Competition Forecast & Opportunities, 2016-2027" report has been added to ResearchAndMarkets.com's offering. The Malaysian Tire Market stood at around USD1.19 billion in 2020 and is expected to register growth with a CAGR of around 5.86% by value terms in the forecast period. Passenger car demand is increasing owing to its usage for daily commutation and due to that vehicle fleet of the country is increasing, consequently, driving the Malaysian Tire Market. Moreover, increasing per capita spending of the people is also resulting in the upgradation of vehicles and hence inducing demand for technologically advanced replacement tires in the country. Continuous business expansion of the worlds' leading tire companies in the country by increasing their product portfolio and customer outreach through more dealer addition is anticipated to intensify the competition in the Malaysian Tire Market over the course of the next five years.The Malaysian Tire Market can be segmented based on vehicle type, by demand category, by company and by region. In terms of vehicle type, the market is segmented into passenger cars, two-wheelers, light commercial vehicles, medium & heavy commercial vehicles & OTR vehicles. Passenger car tires dominated the overall the Malaysian Tire Market in 2020. On the basis of demand category, the replacement market is dominating the Malaysian Tire Market as compared to OEM category. In terms of regional share, the market is segmented into East Malaysia and West Malaysia. As of 2020, East Malaysia dominated the country's tire market owing to better presence of dealers and distributors of automotive tires. In terms of radial vs bias, the market share of radial tires is dominating the Malaysian Tire Market and the trend is expected to continue in the near future.Goodyear Malaysia Berhad, Michelin Malaysia Sdn. Bhd, Continental Tyre Malaysia Sdn Bhd, Bridgestone Tyre Sales (Malaysia) Sdn. Bhd, Hankook Tire Malaysia Sdn. Bhd., Toyo Tyre Malaysia Sdn. Bhd. Maxxis Tires Malaysia., etc. are some of the leading players operating in the Malaysia tire market. Apart from the flagship companies, many Chinese players are also increasing their footprint in the Malaysian Tire Market by pushing their low-cost products blended with ease of availability.Years considered for this report: Historical Period: 2016-2019Base Year: 2020Estimated Year: 2021Forecast Period: 2022-2026 Key Target Audience: Car manufacturing companiesRaw material suppliersDealers/distributors of tiresGovernments and financial institutionsResearch organizations and consulting companiesResearch institutesAssociations, organizations, forums and alliances related to tiresIndustry associationsMarket research and consulting firm Key Topics Covered: 1. Product Overview2. Research Methodology3. Executive Summary4. Voice of Customer4.1. Factors Influencing Purchase Decision4.2. Brand Recall4.3. Brand Switching4.4. Brand Satisfaction Level5. Malaysia Tire Market Outlook5.1. Market Size & Forecast5.1.1. By Value (USD Billion) & Volume (Million Unit)5.2. Market Share & Forecast5.2.1. By Vehicle Type (Passenger Car, Two-Wheeler, Light Commercial Vehicles, Medium & Heavy Commercial Vehicles and OTR vehicles)5.2.2. By Demand Category (OEM vs. Replacement)5.2.3. By Radial vs. Bias5.2.4. By Company (2020)5.2.5. By Region (East Malaysia and West Malaysia)5.3. Product Market Map (By Vehicle Type)6. Malaysia Passenger Car Tire Market Outlook6.1. Market Size & Forecast6.1.1. By Value & Volume6.2. Market Share & Forecast6.2.1. By Vehicle Type (Sedan & Hatchback, SUV, MPV and Window Van)6.3. Product Market Map (By Vehicle Type)7. Malaysia Two-Wheeler Tire Market Outlook7.1. Market Size & Forecast7.1.1. By Value & Volume7.2. Market Share & Forecast7.2.1. By Vehicle Type (Motorcycle & Scooters/Mopeds)7.3. Product Market Map (By Vehicle Type)8. Malaysia Light Commercial Vehicle (LCV) Tire Market Outlook8.1. Market Size & Forecast8.1.1. By Value & Volume8.2. Market Share & Forecast8.2.1. By Vehicle Type (Pickup Truck & Panel Van)8.3. Product Market Map (By Vehicle Type)9. Malaysia Medium & Heavy Commercial Vehicle (M&HCV) Tire Market Outlook9.1. Market Size & Forecast9.1.1. By Value & Volume9.2. Market Share & Forecast9.2.1. By Vehicle Type (Truck, Bus & Heavy Truck)9.2.2. By End Use (Logistics, Construction and Public Transport)9.3. Product Market Map (By Vehicle Type)10. Malaysia OTR Vehicles Tire Market Outlook10.1. Market Size & Forecast10.1.1. By Value & Volume10.2. Market Share & Forecast10.2.1. By Vehicle Type (Mining, Construction and Industrial, Agricultural and Others)10.3. Product Market Map (By Vehicle Type)11. Import-Export Analysis12. Market Dynamics12.1. Drivers12.2. Challenges13. Market Trends & Developments14. Policy and Regulatory Landscape15. Malaysia Economic Profile16. Impact of COVID-19 on Malaysia Tire Market17. Competitive Landscape17.1. Goodyear Malaysia Berhad17.2. Michelin Malaysia Sdn. Bhd17.3. Continental Tyre Malaysia Sdn Bhd17.4. Bridgestone Tyre Sales (Malaysia) Sdn. Bhd17.5. Hankook Tire Malaysia Sdn. Bhd.17.6. Toyo Tyre Malaysia Sdn. Bhd17.7. Maxxis Tires Malaysia17.8. Giti Tire Pte. Ltd17.9. Sumitomo Rubber Industries, Ltd.17.10. The Yokohama Rubber Co., Ltd.18. Strategic RecommendationsFor more information about this report visit https://www.researchandmarkets.com/r/b2d7og CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The Tuacahn Center for the Arts has partnered with Nomi Health, the direct healthcare company coordinating COVID-19 testing and vaccination efforts across the country, for the theatre’s end-to-end COVID-19 testing program. As the largest professional outdoor theatre in Utah, Tuacahn is using Nomi to test an average of 100-250 employees including actors, directors, designers, musicians, technicians and crew, each day, requiring an average of three PCR tests per week. Celebrating its 25th year as a performing arts center, Tuacahn’s testing initiative is the final step to opening its doors and welcoming back its 300,000 patrons for its professional live Broadway performances, starting May 7th for a preview of Disney's Beauty and the Beast preview and May 14th for a preview of Annie.